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Case presentation
Two weeks after admission to the hospital, a 53-year-old woman with
regional enteritis developed restlessness, paresthesias, weakness, ab-
dominal distention, and hypoventilation.
The patient was well until 2 years before admission, when she began
vomiting daily. One year before admission she developed intermittent
abdominal pain without relation to food intake or bowel movements.
Her stools were loose but contained no blood or mucus. In association
with these symptoms and a diet consisting almost exclusively of baked
brains and raw liver, she began to lose weight and was admitted to
another hospital. Anorexia nervosa was diagnosed at that time. tn the 4
months prior to admission, weight loss accelerated and in that period
the patient's weight fell from 55 to 40 kg.
On admission to the Klinikum der Universität Heidelberg, she
appeared markedly malnoirished. Blood pressure was 90/60 mm Hg:
pulse was 88 per minute. The liver was palpable but not tender. The
spleen was not palpable. Bilateral pretibial edema was present. The
right leg was markedly swollen but nontender on palpation, and
Homan's sign was negative. Diffuse muscle wasting was prominent, but
neurologic examination was normal. Laboratory findings disclosed:
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hemoglobin, 11.2 g/dl; white blood cell count, 11,500/mm3, with 1%
metamyelocytes and toxic granulations. Platelet count was 544,000/
mm3. The sedimentation rate was 12 to 19mm/hour. Serum electrolytes
were: sodium, 128 mEq/liter; potassium 3.1 mEq/liter; chloride. 92
mEq/liter; and bicarbonate, 24 mEq/liter. Blood pH was 7.48: PaCO2,
31 mm Hg; serum calcium, 3.3 mEq/liter; serum phosphorus, 2.8 to 3.7
mg/dl; total serum protein, 3.0 to 3.8 g/dl; plasma urea nitrogen. 9 mg/dl;
plasma creatinine, 0.6 mg/dl; plasma cholesterol, 76 mg/dl; and folate,
17 nM/liter. The plasma 25-OH vitamin D concentration was 99 nM/liter
(normal). Prothrombin time was 65%. Serum IgG was 817 mg/dl; IgA,
14 mg/dl; 1gM, 88 mg/dl: plasma fibrinogen, 210 mg/dl (all reduced).
Serum CH30 was 180 U. Serum iron was 22 p.g, and iron binding
capacity was 101 g/dl.
The patient was suspected of having deep-vein thrombosis in the right
leg and was treated with urokinase, heparin, and indomethacin. An
extensive gastrointestinal evaluation was performed to evaluate the
cause of the weight loss and presumed malabsorption. Gastroscopy
revealed no ulcers or erosions, but gastric biopsy disclosed intestinal
metaplasia of the gastric mucosa. An upper gastrointestinal series
disclosed minor segmental narrowing of the distal jejunum and proximal
ileum and spotty filling of the ileum. The findings were not thought to be
consistent with regional enteritis, but were compatible with malabsorp-
tion. Studies of absorption showed: xylose test, 3.34 g/5 hours (low):
fecal chymotrypsin excretion, 62.4 U/g (normal, 120 U/g). Fecal fat
excretion was 20.9 g/24 hours (normal < 7 g/24 hours). Excretion of
311-PVP was 1.47% of dose/4 days (normal). Stool examination for
parasites, pathogenic bacteria, and fungi was negative.
The patient failed to gain weight and on the 13th hospital day
parenteral nutrition was initiated. The patient received 418 g of glucose
per 24 hours, synthetic L-amino acids (8.03 g alphaamino nitrogen/24
hours), xylitol (100 g/24 hours), lactate (II mmol/24 hours), acetate (59
mmol/24 hours), regular insulin (24 U/24 hours), sodium (75 mmol/24
hours), potassium (65 to 145 mmol/24 hours), phosphate (9 mM/24
hours), and a polyvitamin preparation in a total volume of 2.5 liter/24
hours.
On the 16th hospital day, the patient's temperature increased to
38.4° C, but there were no shaking chills. At that time, the white blood
cell count was 14,300/mm3 without a left shift. Fever subsequently
disappeared without antibiotic administration.
On the 19th hospital day, the patient became progressively restless
and complained of circumoral and fingertip tingling followed by general-
ized numbness. She was lethargic and slightly disoriented, but other-
wise mentation was normal. She had marked asthenia, was unable to sit
up, and had difficulty swallowing. Respiration was labored and her
speech had a nasal quality. On examination the temperature was 38.4°
C, blood pressure was 75/60 him Hg, pulse was 120/minute, the
abdomen was distended, and bowel sounds were scarce. Her speech
had a nasal quality, she was unable to raise her head from the pillow,
bilateral ptosis was present, and the gag reflex was diminished. Deep
tendon reflexes were difficult to elicit, but there was a flexor plantar
response and the sensory examination was normal.
An abdominal plain film showed excessive amounts of gas and
several air-fluid levels in the small intestine. Hemoglobin was 6.6 g/dl;
LDH, 160 tU; serum sodium was 114 mEq/liter; uric acid, 2.0 mg/dl;
plasma creatinine, 0.4 mg/dl. Blood gases showed: PaO2, 88 mm Hg;
PaCO2, 54 mm Hg; pH, 7.40. Serum calcium was 3.1 mEq/liter, and
serum phosphorus was 0.25 mg/dl. Creatinine phosphokinase was
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normal. Urinary myoglobin was not measured. Lumbar puncture was
normal and the electroencephalogram showed only slowing of the
rhythm and reduction of amplitude.
The patient was treated with hypertonic sodium chloride, albumin
(400 ml), and macromolecular dextran (500 ml). On the 20th hospital
day, treatment was instituted with intravenous potassium phosphate (20
mmol daily). By the 23rd day, hypotension, ileus, and the neurologic
signs as well as hypercapnia had disappeared. Blood gases on that day
showed P02, 94 mm Hg; PCO2, 28 mm Hg; blood pH, 7.52; and
bicarbonate, 25 mEq/liter.
Parenteral nutrition containing phosphorus was continued, but the
patient failed to gain weight, and she left the hospital against medical
advice. Two months later she died at home. Autopsy revealed regional
enteritis of the upper jejunum with multiple ulcers, stenosis, and
perforation.
Discussion
PROF. MED. EBERHARD RITZ (Head, Division of Nephrolo-
gy, University of Heidelberg, Heidelberg, Federal Republic of
Germany): The multisystem disorder of acute hypophosphate-
mia and acute ventilatory failure is rarely encountered today,
but the underlying pathophysiology is highly instructive and
merits detailed analysis.
The patientunder discussion suffered from Crohn's disease.
The diagnosis of anorexia nervosa was first entertained because
of food idiosyncracies and unusual personality traits, but noth-
ing in her history suggested anorexia nervosa, and food faddism
is not unusual in Crohn's disease. The findings that pointed to
Crohn's disease were her history of abdominal complaints and
weight loss with leukocytosis and thrombocytosis. The low
sedimentation rate in this patient is unusual for Crohn's disease,
but hypofibrinogenemia secondary to severe hypoproteinemia
may account for this finding. Various tests pointed to malab-
sorption possibly caused by bacterial overgrowth. The diagno-
sis of Crohn's disease was not established during the patient's
hospitalization because the small jejunal segment involved
escaped detection on the upper GI series. The diagnosis was
unequivocally confirmed at autopsy, however.
It is interesting that many cases of acute iatrogenic hypophos-
phatemia with neuromuscular disturbances are described in
patients with Crohn's disease [1, 2] and in those with alcoholism
131. Let us focus on the dramatic neuromuscular, cardiovascu-
lar, and hematologic alterations in this woman when parenteral
hyperalimentation was instituted to treat the well-established
malnutrition. Before doing so, I plan to discuss the diagnosis
and mechanisms of phosphate depletion.
Diagnosis of preexisting phosphate depletion
Let us explore first whether the patient was phosphorus
depleted prior to receiving intravenous hyperalimentation. Un-
fortunately we are given conflicting clues. Evidence favoring
such a contention can be adduced from the low plasma phos-
phorus value (2.9 mg/dl) before parenteral hyperalimentation
was begun and from the low urinary phosphorus excretion on
the first day of hyperalimentation (0.124 g/24 hours or 0.277 g
phosphorus/g creatinine). The response of the kidney to phos-
phate depletion provides an explanation for this assertion.
Under ordinary circumstances, phosphate depletion is effec-
tively prevented by the kidney's ability to conserve phosphorus
in response to the body's need for it. It has been demonstrated
in experimental studies that the net load of phosphorus ab-
sorbed from the gut [4], or more specifically the body's phos-
phorus requirements [5], are the most important determinants
for the renal tubular phosphorus threshold. In the proximal
tubule, the permeability of the luminal brush border membrane
is modulated in response to changes of phosphorus balance [6].
As a result, urinary phosphate excretion is low in phosphate
depletion, and this finding can be used to support the diagnosis.
Indeed, in the classic study of Lotz, Zisman, and Bartter,
phosphorus vanished completely from the urine within a few
days in human volunteers given a low-phosphorus diet and oral
phosphate binders [7].
The low urinary phosphate level in this patient argues against
a renal source of phosphate wasting but does not exclude it with
certainty. Recent findings suggest that glucocorticoids can
cause phosphaturia even in the presence of hypophosphatemia
[8]; since glucocorticoid excess cannot be excluded entirely, it
is possible that renal phosphate wasting contributed to deple-
tion in this patient. Episodes of ketoacidosis also are known to
cause phosphaturia [91 secondary to decomposition of organic
phosphate within cells [10] and, although it is possible that
ketoacidotic episodes occurred in our patient, it seems quite
unlikely.
One might argue that the low serum phosphorus levels
provide only weak confirmatory evidence of phosphate deple-
tion. It is known, for example, that hypocapnia tends to lower
plasma phosphorus levels without affecting total-body phospho-
rus [111. Because only 0.1% of total-body phosphate is con-
tained in the extracellular compartment, loss of only a minute
fraction of total-body phosphate from the extracellular com-
partment could cause significant hypophosphatemia. Thus, we
could conclude that the patient was not phosphorus depleted
before parenteral nutrition was instituted. This conclusion
would be in line with previous clinical and experimental studies
112, 13], which suggest that starvation is associated with "an
orderly shrinkage of cellular mass so that the general relation-
ships between nitrogen, phosphorus, potassium and other intra-
cellular components remain nearly normal" [13].
That more than I or 2 days elapsed between the introduction
of parenteral alimentation in this patient and clinical manifesta-
tions of phosphate depletion also argues against preexisting
phosphate depletion. Thus, in the presence of preexisting
phosphorus deficiency (for example, in diabetic ketoacidosis
and alcoholism), hypophosphatemia usually occurs within I or
2 days after hyperalimentation is begun, whereas in patients not
phosphate depleted, hypophosphatemia usually does not be-
come manifest for 5 to 10 days. The patient under discussion
today developed manifestations approximately 5 days after
hyperalimentation was started.
Table 1 displays the many conditions in which hypophospha-
temia can be observed 1141. In these various disorders, at what
serum phosphorus level are clinical manifestations to be expect-
ed? Clinical manifestations usually are not observed until serum
phosphorus falls below 1 mg/dl, and the phosphorus level in the
patient discussed here was well below this concentration. Only
a few clinical conditions lead to such severe hypophosphatemia
113, 15, 16].
Although we are concerned today about acute phosphorus
depletion, it is worthy of note that chronic phosphorus deple-
tion has been a problem to dairy farmers for decades [17].
Because they crave phosphorus when grazing on phosphorus-
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Table 1. Conditions predisposing to phosphate depletion and
hypophosphatemia
1. Parenteral hyperalimentation
2. Alcoholism
3. Recovery phase from diabetic ketoacidosis
4. Recovery/diuretic phase after severe burns
5. Recovery after starvation
6. Overadministration of oral phosphate-binders [Al (OH)3]
depleted pastures, cows devour animal cadavers. These ani-
mals often die of botulism after ingesting spores of C. botulinum
because phosphorus depletion impairs their leukocyte function.
Impairment of neuromuscular function secondary to phospho-
rus depletion also might be a contributing factor. In humans,
despite isolated anecdotal observations [18], not until the report
by Lotz, Zisman, and Bartter [7] did clinicians become interest-
ed in phosphorus depletion.
Serum versus total-body phosphorus
So far, I have used little semantic caution in distinguishing
hypophosphatemia from phosphorus depletion. The two are not
synonymous, however, and hypophosphatemia may not neces-
sarily be associated with phosphorus depletion. Cellular phos-
phorus content is the net result of different transmembrane
fluxes [19]; a remarkable dissociation between ambient plasma
phosphate concentration and cellular phosphorus content is, for
instance, present in genetic disorders such as X-linked hypo-
phosphatemia. Furthermore, cellular phosphorus shows re-
markable compartmentation [20]. Erythrocytes lack mitochon-
dna, which are a major intracellular repository of phosphorus in
other cells; hence the intracellular phosphorus concentration in
erythrocytes, but not in other cells, follows that of plasma [211.
In somatic cells that can draw on mitochondrial phosphorus
stores, cytosolic phosphorus concentration can be maintained
for a remarkably long period despite hypophosphatemia [22].
Consequently, if one uses plasma phosphorus concentration as
an index of cellular phosphorus depletion, one must be aware
that the relation between plasma phosphorus and intracellular
phosphorus is variable. Even in advanced phosphorus deple-
tion, intracellular phosphorus falls by no more than approxi-
mately 20% when measured in deproteinized tissue samples
[22—24]. The possibility exists that these measurements of
cellular phosphorus content are in error, however, since mea-
surements by nondestructive techniques, such as nuclear mag-
netic resonance [25, 261, give values lower by almost one order
of magnitude. Consequently, it is conceivable that cytosolic
phosphorus concentration is close to nil in phosphorus
depletion.
Mechanisms of phosphate depletion
What was the mechanism by which phosphorus depletion
occurred in the patient under consideration? First let us analyze
the ways by which phosphorus depletion can occur, because
several of them might have existed in this patient. Growing
organisms develop phosphorus depletion on a low-phosphate
diet; this fact prompted a protocol that has become a standard
method of inducing phosphorus depletion in experimental ani-
mals [22]. In humans, premature babies develop rickets when
raised on human milk containing relatively little phosphorus;
the rickets heal readily when the infants are fed cow's milk
containing a relatively large quantity of phosphorus [271.
In the adult, phosphorus depletion either can be due to
negative external phosphorus balance, internal redistribution of
phosphorus, or a combination of both. Negative external phos-
phorus balance with the attendant decrease of total-body phos-
phorus/nitrogen ratio may be caused by diminished intestinal
net absorption (for example, after ingestion of oral phosphate
binders) [281, or by renal phosphorus loss [29]. Internal redistri-
bution of phosphorus may lead to hypophosphatemia and
phosnhorus depletion in critical organs without a necessary
alteration of total-body phosphorus. Movement of inorganic
phosphorus from the extracellular to the intracellular space can
be due to utilization of phosphorus for synthesis of organic
macromolecules (phosphoproteins, phospholipids, phosphory-
lated carbohydrates), as in refeeding after starvation or in
parenteral hyperalirnentation, or it can be due to intracellular
trapping of phosphorus esters (hexose-phosphate, phosphory-
lated nucleotides, etc.), as in respiratory alkalosis or following
the administration of carbohydrates such as fructose [15].
The hazards of refeeding starved individuals have been
known for centuries [30]. When describing the horrors of the
siege of Jerusalem, Josephus Flavius wrote that
some of the deserters . . . fled to the Romans. Their
fate was worse than if they had stayed in the City, and
the hunger they had left behind was, as they discov-
ered, less lethal than the plenty that the Romans
provided. They arrived blown up by starvation as if by
dropsy, then stuffed their empty bellies non-stop till
they burst—except for those who were wise enough to
restrain their appetite and take the unaccustomed food
a little at a time.
Similarly, during World War II, many prisoners withstood
years of starvation but died during hospitalization following
release from captivity [1, 31—34]. In such individuals, it was
noted by some that refeeding with skim milk markedly reduced
mortality [31]. Although detailed studies of blood and urine
chemistry were not possible, it later was claimed that the
phosphorus and potassium content of skim milk might have
been important [13]; this view is supported by experimental
studies [35].
Synthesis of protoplasm involves deposition of nitrogen in
parallel with phosphorus in a ratio of 0.07 g phosphorus/g
nitrogen. As shown during intravenous hyperalimentation of
underweight adults [121, repletion of protoplasm is retarded or
abolished if any one of the following elements is lacking:
nitrogen, phosphorus, sodium, or potassium. Such weight gain
as occurs when nitrogen, sodium, or phosphorus is not provid-
ed is due to enlargement of adipose tissue mass, for which the
only requirement appears to be an abundant supply of glucose.
After hyperalimentation was introduced, a virtual epidemic of
hypophosphatemia was described in hyperalimented patients,
at first in the United States [1], and after some delay in Europe,
perhaps because of the continued use of phosphorus-containing
solutions [36]. Acute hypophosphatemia is observed not only
with intravenous hyperalimentation, but even when 5% glucose
solutions are administered to malnourished alcoholics [3].
The first reason for hypophosphatemia that we can identify in
the patient we are discussing today is the requirement for
phosphorus during anabolism for synthesis of intracellular
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Fig. 1. Fructose metabolism in the liver (Ref. 69).
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phosphoproteins, phospholipids, phosphorylated nucleotides,
and carbohydrate phosphate esters. One additional factor can
be identified, however. It has been known for decades that the
plasma phosphorus level falls in response to glucose [371; such a
decrease is less pronounced in muscle disease and more marked
in starvation or cirrhosis [38, 391. The amount by which
phosphorus falls depends on the relative rates of glycogen
synthesis (which requires little phosphorus), glycolysis, and
utilization of glucose. In fact, changes in plasma phosphorus
(and potassium) are primarily related to glycolysis, which is
accompanied by esterification of Organic phosphate within cells
[40]. For maximum phosphorylation to occur in the glycolytic
process, one mole of glucose must bind the equivalent of four
moles of potassium phosphate. Whereas the fall of plasma
phosphorus after glucose administration usually is modest and
transient, a more pronounced and prolonged decrease of plasma
phosphorus is observed after an infusion of fructose [411.
Phosphorus is trapped intracellularly in hepatocytes as frUc-
tose-l-phosphate (see Fig. I); this process produces profound
hypophosphatemia. Inactivation of cellular phosphate in this
bound form has profound effects. Phosphorus depletion in the
cytosol of hepatocytes [161 is followed by depletion of hepato-
cellular ATP, activation of adenylate deaminase (with forma-
tion of inosine monophosphate and uric acid), inhibition of
gluconeogenesis from lactate, and consequent lactacidemia
[161. This phenomenon is exemplified by the particularly severe
hypophosphatemia in patients with congenital fructose intoler-
ance [42] and in fructose-galactose intolerance [43]. Although
fructose was not given to our patient, these observations are
pertinent because similar changes such as ATP consumption
due to accumulation of alpha-glycerophosphate and depletion
of hepatocellular phosphorus are observed with xylitol in the
isolated perfused rat liver [44]. It is surprising that despite their
known adverse effects on hepatocellular ATP, fructose and
xylitol still are widely employed in some European countries as
a source of energy, especially during the postoperative period
[45]. In our patient, refeeding hypophosphatemia probably was
compounded by the concomitant administration of xylitol. In
this patient, serum uric acid did not increase, as commonly
occurs after fructose or xylitol administration [161; in fact, it
actually decreased. Serum uric acid may be low [461 or high [471
during refeeding. In the absence of information about uric acid
excretion, it is impossible for us to judge the extent to which
uric acid production or renal excretion might have been abnor-
mal in our patient. It is of note, however, that an increased
clearance of uric acid can occur after administration of glucose
and amino acids [46]. Disturbances of proximal tubular function
also have been demonstrated in experimental phosphorus de-
pletion [48—SO], but there was no clinical evidence for such a
disturbance in this patient, particularly no glycosuria.
Clinical manifestations
Because phosphorus is a key element in cellular metabolism,
one would expect that some disturbance of function will be
found in every somatic cell. The clinical manifestations in acute
or chronic hypophosphatemia, however, mainly concern the
neuromuscular, cardiovascular, and hematologic systems. The
factor or factors ultimately responsible for disturbed organ
function in phosphorus depletion are currently unknown. Sev-
eral possibilities have been discussed, such as depletion .of
cellular ATP; tissue hypoxia resulting from low erythrocyte 2,3
DPG; partial blockade of glycolysis because of lack of phospho-
rus as a crucial cofactor at the glyceraldehyde-phosphate-
dehydrogenase step; and change of cytosolic calcium and
hydrogen ion concentrations [13, 15, 16]. Let us now turn to an
explanation of the clinical findings in this patient.
Neuromuscular. The presence of ptosis, dysarthria with
nasal speech, difficulty in swallowing, and alveolar hypoventila-
tion initially raised the suspicion of some form of partial bulbar
palsy. Silvis [11, Newman [3], Oster [21, and Finck [51] have
reported patients with remarkably similar findings. The most
threatening feature of the syndrome, alveolar hypoventilation,
may necessitate the use of mechanical ventilation [2, 3]. Hypo-
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Fig. 2. Relationship between onset of hypophosphatemia and elevation
of creatine phosphokinase activity (Ref. 13).
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ventilation is not uniformly observed in acute hypophosphate-
mia, however. Indeed, some authors even have described
hyperventilation [52]. Hyperventilation may have been the
result of poor tissue oxygenation because of increased oxygen
affinity of hemoglobin, that is, a decrease of P50 secondary to
low erythrocyte 2,3 DPG levels. This constellation contains the
elements of a "vicious circle"; hypophosphatemia causes hy-
perventilation, which in turn leads to respiratory alkalosis,
which provokes even more severe hypophosphatemia. When
alveolar hypoventilation occurs, as in our patient, it points to a
profound disturbance of efferent neuromuscular function. Also,
despite hypercapnia, profound hypophosphatemia was main-
tained. One would expect that intracellular acidosis should
cause egress of phosphorus from cells [101. The normal arterial
pH in our patient in the presence of hypercapnia points to a
mixed type of acid-base abnormality or to laboratory error, but
this possibility was not further pursued at the time.
What is the mechanism of neuromuscular dysfunction? An
increase of intracellular water, sodium, chloride, and a decrease
of transmembrane resting potential were found in the muscles
of hypophosphatemic alcoholics [13]. Similar changes are pres-
ent in hypophosphatemic dogs [26] but not in acutely [27] or
chronically [531 hypophosphatemic rats. In chronically hypo-
phosphatemic individuals, a myopathy occurs that involves
predominantly proximal musculature [54, 55]. This abnormality
may be related to the changes of muscle composition described
above [27, 53—56]. Because depletion of ATP and the fall in
intracellular inorganic phosphorus activates AMP-deaminase,
and because low ATP activates 5'-nucleotidase, the pool of
adenylic acids shrinks and presumably makes muscle cells
unable to withstand episodes of increased demand for ATP, for
example, during strenuous exercise or epileptic fits. Figure 2
describes the reversible elevation of serum creatine phosphoki-
nase in an alcoholic with hypophosphaternia; indeed, rhabdo-
myolysis and acute myoglobinuric renal failure occur in such
patients [131 and can be reproduced in chronically phosphorus-
depleted animals given intravenous hyperalimentation [56].
The muscular manifestations in our patient differ from the
above-mentioned syndromes in several respects. Although she
had considerable weakness, the craniofacial involvement pre-
dominated over the proximal musculature affected. Further-
more, there was no muscle tenderness or elevation of serum
creatine phosphokinase. I am therefore forced to look for
alternative explanations for this type of neuromuscular dys-
function. Acute bulbar symptoms, remarkably similar to the
ones in our patient, were observed in malnourished patients
given hyperalimentation and in alcoholics given 5% glucose
solutions [2, 3, 51, 57, 58]. A myopathic component is not
definitely excluded, but I owe to Dr. Finck in Berlin the
unpublished observation that one consistently finds in such
patients evidence of neural disturbance at the radiculospinal
level. Such disturbances are identified on the electromyogram
as disturbed H reflexes and F waves without abnormalities of
nerve conduction velocity or neuromuscular transmission. Evi-
dence is overwhelming that central nervous system abnormali-
ties, such as obtundation, seizures, tremors, disorientation,
anisocoria, and ballismus result from phosphorus depletion [13,
15, 16]. The multilevel abnormalities of neuromuscular function
in phosphorus depletion are poorly understood and present a
fertile area for future investigation.
Ileus. Another noteworthy finding in our patient was ileus.
Possibly Crohn's disease caused a latent abnormality of gastro-
intestinal motility that became apparent when the patient was
critically ill, Disturbed smooth muscle function secondary to
hypophosphatemia is a definite possibility, particularly in view
of the recent demonstration in our laboratory of abnormalities
of vascular smooth muscle function in hypophosphatemia [59].
Cardiovascular. I now would like to examine another aspect
of the patient's clinical course. During the acute episode, she
developed marked hypotension and tachycardia, which were
attributed to ileus and hypovolemia. Recent findings suggest
alternative possibilities, however. O'Connor, Wheeler, and
Bethune studied critically ill hypophosphatemic patients and
found an increase of the cardiac index despite unchanged or
even decreased preload when phosphorus was administered
[60]. Furthermore, cardiac arrhythmias can occur in acutely
hypophosphatemic patients [51]. Finally, congestive heart fail-
ure that responds to phosphate administration has been ob-
served in individuals who ingested large amounts of oral
phosphate binders [21]. A reversible depression in myocardial
performance also can be demonstrated experimentally in phos-
phorus-deficient dogs; Fuller et al observed a decrease of stroke
volume, peak flow velocity, and maximum left ventricular dP/dt
[61]. More recently, Dr. Kreusser in our laboratory observed
decreased myocardial contractility (Vm) not only in the basal
state, but also in response to catecholaminergic stimulation
(Fig. 3) [621. This abnormality was completely reversible when
phosphorus was administered. In addition, the hypophosphate-
mic dogs' failure to show an adequate pressor response to
angiotensin, and the reversal of this response with phosphate
repletion, point to a vascular muscle abnormality induced by
phosphorus depletion. In view of this experimental evidence,
compromised cardiovascular function is likely an added risk in
critically ill, acutely hypophosphatemic individuals, and al-
though documentation is far from perfect, this situation may
have been present in the patient under consideration.
Red blood cells. Let me comment on two findings in our
patient that point to possible hematologic disturbances. Hemo-
globin levels decreased from 9.2 to 6.6 g/dl. Although no further
investigations were carried out in this patient, hemolytic anemia
in severe hypophosphatemia has been documented [47, 52, 63].
Several abnormalities of erythrocyte function have been docu-
mented in hypophosphatemic patients and experimental ani-
mals [63]. Phosphate is a critical cofactor for the glyceraldehyde
phosphate-dehydrogenase step of glycolysis [47, 521. In hypo-
phosphatemia, a block of glycolysis occurs with a fall of 2,3
DPG and the other intermediates distal to this step. Deficiency
of ATP and particularly 2,3 DPG shift the position of the
oxygen-hemoglobin equilibrium curve to the left (Fig. 4). This
shift increases the affinity of hemoglobin for oxygen and
deprives tissues of oxygen. Furthermore, fluidity and elastovis-
cous properties of the erythrocyte membrane crucially depend
on the microfilamental system, which consists of actin and
myosin analogues and which requires ATP for proper function.
Loss of ATP causes rigidity and insufficient deformability of
erythrocytes and leads to erthyrocyte fragmentation in the
microvasculature. Hemolysis occurs when the serum phospho-
rus level falls below 0.5 mg/dl [13].
Leukocytes. The transient fever in our patient also deserves
comment. Craddock et al found a significant depression of
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phosphate repletion. The animals were studied under basal conditions
(Bas) and after stimulation with angiotensin II (All), norepinephrine
(NA), and orciprenaline (Ore). HR refers to heart rate; EDP refers to
left ventricular end diastolic pressure; LVP refers to left ventricular
peak systolic pressure; Vi,,,, refers to maximal contractile element
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62).
chemotactic, phagocytic, and bactericidal activity of granulo-
cytes of phosphate-depleted dogs [641. The ATP concentration
in granulocytes increases and the motility defect is corrected
when phosphorus is repleted in vivo by supplementation of the
diet or in vitro by incubation of the leukocytes with adenosine
and phosphate. It appears likely that phosphorus depletion, by
reducing ATP synthesis, interferes with the microtubular sys-
tem that regulates the mechanical properties of leukocytes
(pseudopod and vacuole formation) and also interferes with
microfilaments that control surface movement. In addition,
phosphorus depletion may impair the requirement for increased
synthesis of phosphoinositides and other organic phosphate
compounds of the cell membrane during phagocytosis. Synthe-
sis of membrane material may be compromised; abnormalities
of membrane phospholipids have been noted by Klock and
Shohet in erythrocytes [65] and by our laboratory in subcellular
muscle membranes [27]. The increased incidence of septicemia
in patients on total parenteral hyperalimentation has been
attributed to defective leukocyte function [13, 64], but local
hypertonicity at the site of the central catheter may be an added
factor since phagocytic function is impaired by high osmolality.
Fig. 4. Oxyhemoglobin dissociation and the effects of acidosis, alkalo-
sis, and phosphate depletion (after Ref. 15).
The potential importance of phosphorus for resistence to bacte-
rial infection is well documented by experimental studies.
Garner, Huebner, and O'Dell demonstrated that phosphorus
administration to hypophosphatemic animals with salmonella
septicemia markedly reduced mortality [66].
Phosphorus is crucial for the function of every somatic cell. It
is not surprising therefore that phosphate depletion alters the
function of virtually every organ. A number of alterations in our
patient, such as electrolyte changes and hepatic function, would
merit further comment. But I would like to close on a short note
concerning prevention of such unfortunate episodes.
Prevention. Dangerous hypophosphatemia during hyperali-
mentation can safely be prevented if potassium dihydrogen
phosphate, 20 to 25 mEq/l .000 kcal, is administered prophylac-
tically [36]. Detailed guidelines for hyperalimentation of under-
nourished adults have been given by Rudman et al, who
recommend 0.4 g/kg ideal body weight of sodium per day and
0.018 g/kg ideal body weight of phosphorus per day if no
extrarenal losses of body fluid (diarrhea, vomiting, gastric
suction, fistula) or hypermetabolic states (infection, trauma,
fever) are present [12]. The practical details of phosphorus
administration, particularly the prevention of dangerous hypo-
calcemia, recently have been dealt with in detail [67]. Suffice it
to say that the kidney is usually wiser than the physician and
signals adequate replacement by spilling phosphate into the
urine when phosphate depletion has been reversed.
Questions and answers
DR. JEROME P. KASSIRER: Thank you, Dr. Ritz. Given the
complex clinical setting in which phosphate depletion develops,
how can you identify whether the manifestations of such
patients are caused by phosphate depletion?
DR. RITz: Clinical signs and symptoms of phosphate deple-
tion usually are observed at serum phosphorus levels below
1 mg/dl, and such low levels usually indicate phosphorus
depletion. When urinary phosphorus is low or absent in the
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presence of marked hypophosphatemia, phosphorus depletion
is virtually certain. Although important symptoms usually are
not observed at serum phosphorus levels above 1 mg/dl, lesser
degrees of hypophosphatemia (2—3 mg/dl) still might indicate
phosphate depletion severe enough to prevent maximum
anabolism.
DR. KASSIRER: What is the best method of treating the patient
acutely depleted of phosphate?
DR. RITZ: One approach is oral administration of phospho-
rus. This route is preferable because it avoids some of the
hazards associated with intravenous administration. If one
gives phosphorus slowly, the body has time to adapt and self-
correct the abnormalities that lead to such hazards. If the
patient is unable to tolerate oral phosphate administration or if
there is a medical emergency, one can administer phosphorus
intravenously. One must be cognizant, however, of some
potential complications. First, if a severely phosphorus-deplet-
ed patient is given phosphorus intravenously, profound hypo-
calcemia may ensue. For example, Drs. Rambausek and
Kreusser administered phosphorus intravenously to chronically
phosphorus-depleted rats and lost almost all of the animals;
death was prevented by the simultaneous administration of
calcium [68]. By administering radiocalcium they showed that
phosphorus was translocated into cells of soft tissue, predomi-
nantly muscle, and was accompanied by an equivalent amount
of calcium. The most important consideration during intrave-
nous administration of phosphorus is avoidance of severe
hypocalcemia because it can be complicated by shock and
cardiac arrhythmias. Of course, if calcium is administered
intravenously, it is important that it not be given in the same
venous line as phosphorus because precipitation will occur
promptly. As I mentioned previously, detailed recommenda-
tions for dosage have been given in a recent report, and I refer
you to that communication for details [67].
To assure that the patient has been given an adequate amount
of phosphorus, the clinician has available one simple proce-
dure, determination of urinary phosphorus. in the absence of a
renal tubular absorptive abnormality, urinary phosphorus is the
best index of adequate phosphorus repletion.
DR. KASSIRER: Suppose you are dealing with an urgent
situation: this patient, for example, became moderately hyper-
capnic and warranted rapid repletion of phosphorus. Would it
be appropriate to give the patient intravenous sodium or
potassium phosphate and follow the serum calcium level
frequently?
DR. RITZ: Yes, this is precisely what I would suggest in such
a case.
DR. KASSIRER: Certain features in this patient raise the
possibility that there might be a renal diluting defect. The
combination of severe hypouricemia, hyponatremia, and a low
serum creatinine level strongly suggests to me that the patient
had the syndrome of inappropriate ADH secretion. If an
excessively high water intake was not the cause (and there is no
history to indicate that it was), then we must conclude that a
diluting defect was present. Is there any evidence that phos-
phate depletion influences ADH production or release or the
local effect of ADH on the kidney? Or does phosphate depletion
affect the diluting mechanism independently of ADH?
DR. RITZ: There is some experimental evidence of increased
V/C1 and C,o/C1 associated with increased fractional delivery
out of the proximal tubule in phosphorus-depleted animals
during acute water diuresis [481, and these abnormalities are
promptly reversed by phosphorus repletion. There is no infor-
mation, to the best of my knowledge, about ADH secretion and
ADH response in chronic phosphorus depletion. I pointed out
that phosphorus depletion has been investigated intensely only
in the last few years; many aspects are still "terra incognita"
for renal physiologists. In this particular patient documentation
is poor, but the occurrence of ADH oversecretion as a result of
nonosinotic stimuli is a good possibility.
DR. KASSIRER: Does phosphate depletion have important
acid-base consequences? Because these depleted patients ex-
crete little phosphate, their titratable acid excretion must be
very low, and this disorder theoretically could lead to a defect
in urinary acid excretion. Do these patients often have a mild
metabolic acidosis, or does increased ammonia production
make up for the reduction in titratable acid excretion?
DR. RITZ: Titratable acid excretion, ammonia excretion, and
bicarbonate reabsorption all are abnormal in phosphorus deple-
tion. The bicarbonate threshold of the kidney is low, presum-
ably because of increased cytosolic pH in proximal tubular
cells, as suggested by measurements with the DM0 technique
[50]. Further, there is an abnormality of urinary ammonia
excretion over and above diminished ammonia trapping as a
result of alkaline urine pH [69]. Finally, titratable acid by
necessity must be reduced because excretion of phosphate, the
most important proton acceptor, is low.
To make a long story short, there is a tendency for proton
retention in phosphorus depletion. Paradoxically, however,
arterial pH usually is normal in the early phase of phosphorus
depletion. Consequently, there must be some source of alkali
that titrates the protons retained by the kidney. Bone hydroxy-
apatite presumably constitutes the source of such alkali [70]. I
don't want to go through the stoichiometry, but dissolution of
tertiary calcium phosphate consumes acid equivalents. On
balance, this allows the body to maintain normal pH at the
expense of consuming some skeletal alkali.
DR. KASSIRER: One other possibility, of course, is that the
meager food intake greatlyreduces acid production. Therefore,
even though there is a defect in renal acid excretion, acidosis
does not occur because the input of acid is so low.
DR. RITZ: You are correct in pointing to this possibility. This
consideration, however, does not apply to the experimental
models of phosphorus depletion that demonstrate the abnormal-
ities of tubular acid transport mentioned earlier.
PROF. DR. OTTO MEHLS (Assoc. Prof. of Pediatrics, Heidel-
berg): Dr. Ritz, could you tell me how often and under what
conditions hypercalcemia occurs in patients with hypophospha-
temia? In the study on phosphorus depletion in healthy volun-
teers that you mentioned, hypercalcemia was not noted. I ask
this question because I have observed marked hypercalcemia in
2 children with severe hypophosphatemia. Hypercalcemia in
one child was so pronounced that we were unable to resolve it
with peritoneal dialysis. This latter patient was on hemodialysis
and had been treated with hyperalimentation without phospho-
rus supplementation.
DR. RITZ: Am I correct in assuming that vitamin D intoxica-
tion, uncontrolled hyperparathyroidism, or hypercalcemia from
immobilization cannot account for your observation?
DR. MEHLS: Yes.
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DR. RITZ: There are enormous species differences with
respect to serum calcium levels in hypophosphatemia. In the
phosphorus-depleted rat, hypercalcemia is constant, at least
during the first 3 weeks of phosphorus depletion [71]. The
serum calcium level later decreases for at least two reasons:
first, indirect evidence exists for inappropriately low parathy-
roid hormone levels [721; second, there is an abnormality of
osteocyte ultrastructure in phosphorus depletion as shown in
Kreusser's study.
Apparently, humans differ from rats with respect to serum
calcium levels during phosphorus depletion. Humans usually
are normocalcemic despite increased intestinal absorption of
calcium and the development of hypercalciuria. I am aware of
occasional phosphorus-depleted adult patients who developed
hypercalcemia during administration of thiazides (Massry S,
personal communication), but this phenomenon seems to be the
exception rather than the rule. But children may well differ from
adults in this respect. I believe this issue has not been investi-
gated. Finally, as the most likely explanation, I would propose
that your children had marked (renal) secondary hyperpara-
thyroidism; it is well known that if one lowers serum phospho-
rus in such individuals (for example, after transplantation), the
serum calcium level will rise.
DR. MEHLS: The observation of hypercalcemia in hypophos-
phatemic children seems to be consistent, since I observed it in
3 children. A causal relationship is suggested by the observation
that serum calcium levels promptly returned to normal upon
administration of phosphorus, whereas hypercalcemia had been
resistant even to peritoneal dialysis prior to phosphorus
repletion.
DR. PETER GROSS (Nephrolo gist, Division of Nephrology,
Heidelberg): Could hypercalcemia be explained by an increased
efflux of phosphorus and calcium from bone? According to Dr.
Kreusser this disturbance is observed in phosphorus depletion.
DR. RITz: There is good experimental evidence in phospho-
rus depletion for bone mineral mobilization by osteoclasts
independent of PTH [731, but increased bone mineral mobiliza-
tion does not by necessity lead to hypercalcemia. This is well
exemplified, for instance, by Paget's disease. We are certainly
more at a loss to explain why humans do not develop hypercal-
cemia than to explain why rats do develop hypercalcemia.
DR. ALEXANDRA KETTNER (Nephrologist, Stiftung Rehabili-
tation, Heidelberg): I would like to pursue this point a bit
further. The body has enormous phosphorus stores in bone. I
wonder why such bone mineral phosphorus stores are not
mobilized in individuals with phosphorus depletion so that
normal phosphate levels are restored? Is it possible that the
absence of hypercalcemia in humans, in contradistinction to its
presence in rats, might point to inadequate bone mineral
mobilization?
DR. RITZ: With respect to mobilization of bone mineral, it is
helpful to distinguish between acute and chronic hypophospha-
temia. In acute hypophosphatemia usually due to acute internal
redistribution of phosphorus, bone is certainly too bradytrophic
to mobilize the enormous amounts of calcium and phosphorus
that would be required to correct hypophosphatemia. In chron-
ic hypophosphatemia, bone mineral is mobilized by the action
of osteoclasts and osteocytes even though PTH levels are low.
The paradoxical activation of osteoclasts despite the absence of
a PTH stimulus points to the lack of phosphorus as an important
direct or indirect signal for bone cells [74]. Stimulation of bone
cells through the signal of hypophosphatemia is homeostatically
useful: phosphorus mobilized from bone is used to refill the
phosphorus deficit of extracellular fluid and tissue stores,
whereas calcium that is concomitantly mobilized is spilled into
urine and accounts, at least in part, for hypercalciuria. As I
mentioned before, bone mineral mobilization also is important
for the provision of alkali and the correction of early metabolic
acidosis resulting from abnormal tubular handling of acid.
DR. KETTNER: Are plasma l,25(OH)2-vitamin D3 levels nor-
mal in hypophosphatemic patients?
DR. RITZ: Dr. Haussler found plasma l,25(OH)2D3 levels to
be increased in hypophosphatemic rats [75, 76]. This is not very
surprising in view of the fact that phosphorus is one of the
signals that controls the activity of 1-alpha-hydroxylase in the
proximal tubule. Whether l,25(OH)2D3 plays a role as a PTH-
independent signal to bone cells, as described above, has not
been well established.
DR. KETTNER: You mentioned the danger of hypocalcemia
during phosphorus depletion. Is there any evidence for a role of
PTH in this condition? Does the incidence of hypocalcemia
differ in parathyroidectomized animals?
DR. RITZ: This issue has not been well investigated. Dr.
Kreusser and Dr. Rambausek have evidence that PTH activity
and fractional urinary cAMP excretion rise while plasma calci-
um levels fall during acute intravenous phosphorus repletion in
phosphate-depleted rats [68]. The parathyroid glands are proba-
bly chronically suppressed in this condition as a consequence of
hypercalcemia, so that the rise in plasma PTH concentration is
inappropriate. In the above experiments, however, hypocalce-
mia could not be prevented by administration of exogenous
PTH; this indicates that an element of PTH resistance also is
involved. Radiocalcium studies showed that during phosphorus
repletion, calcium is acutely translocated to muscle and internal
organs and to a negligible extent to bone, in parallel with
phosphorus.
DR. WILHELM KREUSSER (Nephrolo gist, Division of
Nephrology, Heidelberg): Is there evidence that correction of
hypophosphatemia is important for control of infection?
DR. RITZ: Garner, Heubner, and O'Dell studied guinea pigs
with salmonella septicemia. Such animals hyperventilate and
consequently have hypophosphatemia. If phosphorus is admin-
istered to such animals, mortality is dramatically reduced [66].
For obvious reasons, there exist no formal studies on this
question in humans, but hyperventilation and hypophosphate-
mia are common consequences of gram-negative septicemia.
Consequently, correction of hypophosphatemia should be part
of the management of the septicemic patient. Whether such
correction is beneficial only in severe hypophosphatemia or
also in less severe hypophosphatemia is unknown.
DR. WOLFGANG TSCHOPE (Nephrolo gist, Division of
Nephrology, Heidelberg): Can one readily calculate the phos-
phorus deficit in a hypophosphatemic patient prior to phospho-
rus repletion?
DR. RITZ: There is no clear-cut linear relationship between
serum phosphorus levels and the degree of phosphorus deple-
tion for the reasons I outlined earlier. Erythrocyte phosphorus
is of no help in assessing body phosphorus stores because
erythrocyte phosphorus parallels plasma phosphorus levels
[77—791. What one really would like to know is the whole-body
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phosphorus:nitrogen ratio, but this information is not available
in the clinical setting. So the only practical advice is, make an
educated guess and treat the patient carefully with phosphorus
until urinary phosphorus is restored to normal.
DR. KASSIRER: It seems to me that treating hypophosphate-
mia is analogous to treating hypokalemia or hypomagnesemia.
When a patient's serum potassium or magnesium level is low,
one doesn't know precisely the extent of the deficit. In both
instances usually we cautiously administer potassium or magne-
sium until the plasma level rises. In the case of phosphate
administration, one has to be careful not to give phosphate so
rapidly that serum calcium falls to dangerously low levels.
DR. TSCHOPE: In patients on parenteral hyperalimentation,
blood glucose levels can easily rise into the hyperglycemic
range with consequent glycosuria and osmotic diuresis. In view
of such an osmotic diuresis, is urinary phosphorus still a reliable
indicator of body phosphorus stores?
DR. Riiz: You are correct that osmotic diuresis can cause
phosphaturia. This mechanism is particularly important in
causing latent phosphorus depletion in patients with diabetic
ketoacidosis prior to therapy. In fact, neither osmotic diuresis
nor PTH cause much phosphaturia in advanced phosphorus
depletion. But your point is well taken that judging phosphorus
repletion from the urinary phosphorus level is only valid if there
is no osmotic diuresis and if no factors, such as volume
expansion, diuretics, or glucocorticoids, are present that might
interfere with proximal reabsorption.
DR. KREUSSER: Concerning osmotic diuresis, I wanted to add
that according to the studies of Massry and Frick, volume
expansion does not cause phosphaturia in phosphorus depletion
[80, 811. Therefore, I question whether osmotic diuresis really
can cause phosphaturia in an individual with phosphorus deple-
tion. I suspect that a low urinary phosphorus level is still a good
indicator of phosphorus depletion whether or not osmotic
diuresis is present.
DR. RITz: From reverse balance studies, we know that prior
to insulin therapy patients with diabetic ketoacidosis are phos-
phorus depleted and still have phosphaturia. The phosphaturia
rapidly disappears, concomitant with the fall of serum phospho-
rus levels, when insulin therapy is begun, as demonstrated
years ago by Seldin [821. I agree that in advanced phosphorus
depletion, the kidney has an enormous capacity to retain
phosphorus, and that this ability is not overcome by volume
expansion, osmotic diuresis, or PTH.
DR. MICHAEL RAMBAUSEK (Nephrologist, Division of
Nephrology, Heidelberg): I have a question with respect to
low blood pressure in this patient. Could you comment on
the possibility of diminished peripheral resistance in
hypophosphatemia?
DR. RITZ: There is no published information on total periph-
eral resistance in phosphorus depletion. Dr. Kreusser currently
has a study underway in which he measured both the response
of total peripheral resistance to pressor agents in intact phos-
phorus-depleted dogs and the response of resistance vessels to
pressor agents in the isolated perfused hind limb of phosphorus-
depleted rats. He found evidence for an attenuated rise of total
peripheral resistance in phosphorus-depleted dogs in response
to angiotensin II, and he observed similar findings in the
perfused hind limbs, In addition, there is a possibility of
impaired noradrenalin metabolism in the phosphorus-depleted
rat with abnormal reuptake by the rat heart [591.
DR. GRoss: You have recommended assessing urinary or
plasma phosphorus concentrations in judging repletion of phos-
phate stores. Since rhabdomyolysis occurs in phosphorus de-
pletion, aren't you concerned that occasionally urinary phos-
phate would be high despite considerable phosphate depletion?
DR. RITZ: Muscle phosphorus and nucleotide content is in
the millimolar range, so necrosis of sizable amounts of muscle
certainly could deliver phosphorus to the extracellular fluid
space; this phenomenon is commonly observed in myoglobin-
uric acute renal failure. But this condition can be easily
recognized on the basis of clinical findings and very high
creatine phosphokinase levels. When muscle necrosis is pres-
ent, these factors would have to be taken into consideration
when assessing the need for phosphorus supplements.
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